GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life. TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

American Gene Technologies (AGT) is focused on creating long-term value for patients, society, investors and donors by developing and testing cutting-edge gene therapies to cure some of humanity’s worst diseases. AGT’s HIV cure clinical trial could not only lead to a blockbuster drug that brings relief to one of society's most elusive epidemics, but it could prove the efficiency and effectiveness of AGT’s platform technologies to cure dozens of diseases ranging from viruses to cancers.

Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

The Kobayashi Pharmaceutical Group provides a variety of products in fields such as pharmaceuticals, fragrances, dietary supplements and daily necessities. Providing products in these diverse fields is a business activity based on the broader management philosophy of “Providing Great Pleasure to People and Society” regardless of the current business domain. The current management philosophy was newly created in April 1999 by adding the meanings of “creation and innovation” and “Something New Something Different”, which are one of the characteristics of the Kobayashi Pharmaceutical Group, to the conventional management philosophy. is. The Kobayashi Pharmaceutical Group believes that pursuing the provision of “Pleasure” for people and society in this management philosophy is the significance of the Kobayashi Pharmaceutical Group.

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Ruida Health Industry engages in the development of innovative drugs and innovative treatment technologies. The company has established a research and development team of more than 200 people, including more than ten cooperating academicians, winners of the National Outstanding Youth Fund, and winners of important national projects. Ruida Health has deployed the biopharmaceutical industry chain and established industrial entities in Hefei, Huainan, and Hainan. As the R&D base in Hefei High-tech Zone, Ritar Health and the University of Science and Technology of China established the "University of Science and Technology of China-Rida Joint Life Research Center", and the Institute of Advanced Research of the University of Science and Technology of China established the "University of Science and Technology of China-Enkai Immunotherapy Technology Joint Laboratory", "University of Science and Technology of China-Rida Immunotherapy" Joint Laboratory", set up "Anhui Provincial Academician Workstation" and "Anhui Provincial Immunotherapy Engineering Laboratory" to continuously deliver innovative results for the company and quickly realize the transformation of scientific and technological achievements. Sailepu Pharmaceuticals is the production base of APIs. Hainan Boao Ruida Medicel International Medical Center, as a clinical transformation base, relies on the advantages of national policies to carry out clinical applications and provide clinical trial data for the company's new products.

MEDINET Co., Ltd. engages in cell processing business. It offers solutions for regenerative medicine and cell therapy. It operates through the Cell Processing and Regenerative Medical Products segments. The Cell Processing segment includes manufacturing of specific cell-processed products for medical institutions; contracts for clinical and trial cell processing from companies, universities, research institutions; and contracts for operation of cell culture processing facilities. The Regenerative Medical Products segment deals with research and development for the acquisition of manufacturing and marketing approval for regenerative medicine products. The company was founded by Yoshiji Kimura and Kohji Egawa on October 17, 1995 and is headquartered in Tokyo, Japan.

The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. Its work is helping to understand why disease develops and to find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. By bringing together scientists from many disciplines, the Crick will help to improve people's lives and keep the UK at the forefront of innovation in medical research, attracting high-value investment and strengthening the economy.

Qianjing Biotechnology Co., Ltd., established on 2019-08-30, Business scope includes cell technology development(except stem cells);Biotechnology Research,to develop,technical consulting,technology transfer,Technology Promotion,Technical Services;Medical Research and Experimental Development;Sales of class Ι medical devices,Class II medical device;health management(Except for medical treatment activities subject to approval);Health Advisory(Except for medical treatment activities subject to approval);Basic software service;Application software service;Computer System Services;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Import and export,Technology Import and Export;medical service.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Medical services and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

The Child Jesus is the largest Pediatric Clinic and Pediatric Research Center in Europe , linked to major international centers in the field. Nearly 2,600 people work in it, including physicians, researchers, nurses, hospital technicians and clerks . Also the number of patients treated is very large, for a total of over 1 million and 550,000 performances each year to children and children around the world . The size of a city inhabited by children who are cared for, followed and assisted, which are at the center of an affordable, comprehensive and quality healthcare offering.

CSL Innovation Pty Ltd. develops pharmaceutical products. The firm also develops human antibody inhibitors of the granulocyte-macrophage colony stimulating factor receptor alpha subunit, GM-CSFRa, for potential therapeutic use in inflammatory diseases. The company was founded in 1986 and is headquartered in Richmond, Australia.

BioAgency AG is a venture capital firm specializing in investments in startup and early stage. It prefers to invest in life science and biotech companies based in Germany or maximum of one and half hour flight time from Hamburg. The firm typically invests up to €1.5 million ($1.91 million) in series A and B financing. The firm can also invest along with other co-investors. BioAgency AG was founded in December 1999 and is based at Hamburg, Germany.